Edupuganti, S., Hurt, C., Stephenson, K., Huang, Y., Paez, C., Gamble, T., … Tomaras, G. (2022). First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 25, pp. 229–229).

Edupuganti, S., C. Hurt, K. Stephenson, Y. Huang, C. Paez, T. Gamble, C. Yu, et al. “First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25:229–229, 2022.

Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Gamble T, et al. First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022. p. 229–229.

Edupuganti, S., et al. “First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 25, 2022, pp. 229–229.

Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Gamble T, Yu C, Yen C, Regenold S, Chege W, Landovitz RJ, Mayer KH, Siegel M, Sobieszczyk ME, Walsh SR, Heptinstall J, Seaton K, Montefiori D, Tomaras G. First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022. p. 229–229.